Lexicon Pharmaceuticals (LXRX) Net Margin (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 16 years of Net Margin data on file, last reported at 25.1% in Q1 2026.

• On a quarterly basis, Net Margin rose 224487.0% year-over-year to 25.1% in Q1 2026; TTM through Mar 2026 was 61.69%, a 55660.0% increase from a year earlier, with the FY2025 full-year figure at 121.59%, up 186692.0% from the prior year.
• Net Margin for Q1 2026 stood at 25.1%, up from 306.04% in the prior quarter.
• Over the last five years, Net Margin for LXRX reached as high as 14.45% in Q2 2025 and fell as low as 74708.57% in Q2 2022.
• Historically, Net Margin has averaged 11619.81% across 5 years, with a median of 3495.14% in 2024.
• Across the five-year window, Net Margin jumped 5705324 bps in 2023 and slumped 16097 bps in 2025, its largest moves.
• Year by year, Net Margin stood at 74708.57% in 2022, then surged by 91 bps to 6809.14% in 2023, then soared by 98 bps to 145.07% in 2024, then slumped by 111 bps to 306.04% in 2025, then soared by 92 bps to 25.1% in 2026.
• Per Business Quant data, the three most recent Net Margin figures were 25.1% in Q1 2026, 306.04% in Q4 2025, and 117.66% in Q3 2025.